CA1101332A - Procedes simplifies pour la preparation de concentres de facteur viii de tres grande purete - Google Patents
Procedes simplifies pour la preparation de concentres de facteur viii de tres grande pureteInfo
- Publication number
- CA1101332A CA1101332A CA270,497A CA270497A CA1101332A CA 1101332 A CA1101332 A CA 1101332A CA 270497 A CA270497 A CA 270497A CA 1101332 A CA1101332 A CA 1101332A
- Authority
- CA
- Canada
- Prior art keywords
- factor viii
- solution
- buffer
- polyol
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 68
- 239000012141 concentrate Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 5
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 68
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 68
- 238000001556 precipitation Methods 0.000 claims abstract description 33
- 229920005862 polyol Polymers 0.000 claims abstract description 28
- 150000003077 polyols Chemical class 0.000 claims abstract description 28
- 239000007853 buffer solution Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 44
- 102000008946 Fibrinogen Human genes 0.000 claims description 23
- 108010049003 Fibrinogen Proteins 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 23
- 229940012952 fibrinogen Drugs 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 12
- 230000001698 pyrogenic effect Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 239000007979 citrate buffer Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- -1 poly (oxyethylene) Polymers 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000013618 particulate matter Substances 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000006353 oxyethylene group Chemical group 0.000 claims 1
- 239000002510 pyrogen Substances 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 19
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010051124 Hyperfibrinogenaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000013528 metallic particle Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Processing Of Solid Wastes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US653,973 | 1976-01-30 | ||
| US05/653,973 US4069216A (en) | 1975-06-16 | 1976-01-30 | Simplified methods for preparation of very high purity Factor VIII concentrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1101332A true CA1101332A (fr) | 1981-05-19 |
Family
ID=24623016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA270,497A Expired CA1101332A (fr) | 1976-01-30 | 1977-01-26 | Procedes simplifies pour la preparation de concentres de facteur viii de tres grande purete |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS52102410A (no) |
| AR (1) | AR214625A1 (no) |
| AT (1) | AT354632B (no) |
| BE (1) | BE850852A (no) |
| BR (1) | BR7700554A (no) |
| CA (1) | CA1101332A (no) |
| DE (1) | DE2703620C2 (no) |
| DK (1) | DK146855C (no) |
| ES (1) | ES455473A1 (no) |
| FR (1) | FR2339621A1 (no) |
| GB (1) | GB1557609A (no) |
| LU (1) | LU76652A1 (no) |
| MX (1) | MX5197E (no) |
| NL (1) | NL179290C (no) |
| NO (1) | NO145563C (no) |
| SE (1) | SE442953B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE448945B (sv) * | 1979-12-20 | 1987-03-30 | Blombaeck E G B | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
| AT369263B (de) * | 1980-08-27 | 1982-12-27 | Immuno Ag | Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates |
| ATE39324T1 (de) * | 1981-04-08 | 1989-01-15 | Atomic Energy Authority Uk | Blutfraktionierung. |
| US4382028A (en) * | 1982-07-19 | 1983-05-03 | Monsanto Company | Separation of plasma proteins from cell culture systems |
| FR2535173A1 (fr) * | 1982-11-03 | 1984-05-04 | Protein Sa | Produits obtenus a partir de sang d'animaux d'abattoirs et leur procede d'obtention |
| FR2603805A1 (fr) * | 1986-09-16 | 1988-03-18 | Transfusion Sanguine Assoc Rgl | Procede d'inactivation par ozonolyse de micro-organismes contaminants presents dans des materiaux biologiques essentiellement proteiques, les produits obtenus et leurs applications biologiques et analytiques |
| HRP940645A2 (en) * | 1993-10-06 | 1996-12-31 | Immuno Ag | Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained |
| US10035106B2 (en) | 2012-06-26 | 2018-07-31 | Conwed Plastics Llc | Membrane filtration using low energy feed spacer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL286954A (no) * | 1962-01-03 | |||
| US3652530A (en) * | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3631018A (en) * | 1970-05-01 | 1971-12-28 | Baxter Laboratories Inc | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate |
| US3682881A (en) * | 1970-10-02 | 1972-08-08 | Baxter Laboratories Inc | Fractionation of plasma using glycine and polyethylene glycol |
| US3770631A (en) * | 1971-06-29 | 1973-11-06 | Baxter Laboratories Inc | Clarification of blood serum and plasma |
| US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
| US4073886A (en) * | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
| US3893990A (en) * | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene |
-
1977
- 1977-01-26 CA CA270,497A patent/CA1101332A/fr not_active Expired
- 1977-01-27 SE SE7700864A patent/SE442953B/xx not_active IP Right Cessation
- 1977-01-28 NL NLAANVRAGE7700927,A patent/NL179290C/xx not_active IP Right Cessation
- 1977-01-28 GB GB3643/77A patent/GB1557609A/en not_active Expired
- 1977-01-28 DK DK36477A patent/DK146855C/da not_active IP Right Cessation
- 1977-01-28 DE DE2703620A patent/DE2703620C2/de not_active Expired
- 1977-01-28 MX MX775394U patent/MX5197E/es unknown
- 1977-01-28 LU LU76652A patent/LU76652A1/xx unknown
- 1977-01-28 NO NO770293A patent/NO145563C/no unknown
- 1977-01-28 FR FR7702396A patent/FR2339621A1/fr active Granted
- 1977-01-28 BE BE174461A patent/BE850852A/xx not_active IP Right Cessation
- 1977-01-28 BR BR7700554A patent/BR7700554A/pt unknown
- 1977-01-28 AT AT53277A patent/AT354632B/de not_active IP Right Cessation
- 1977-01-28 AR AR266368A patent/AR214625A1/es active
- 1977-01-29 ES ES455473A patent/ES455473A1/es not_active Expired
- 1977-01-31 JP JP959477A patent/JPS52102410A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| MX5197E (es) | 1983-04-25 |
| DK146855B (da) | 1984-01-23 |
| DK36477A (da) | 1977-07-31 |
| NO145563C (no) | 1982-04-21 |
| DK146855C (da) | 1984-07-02 |
| NL179290C (nl) | 1986-08-18 |
| JPS52102410A (en) | 1977-08-27 |
| GB1557609A (en) | 1979-12-12 |
| DE2703620C2 (de) | 1984-11-22 |
| BR7700554A (pt) | 1977-10-04 |
| NO145563B (no) | 1982-01-11 |
| FR2339621A1 (fr) | 1977-08-26 |
| LU76652A1 (no) | 1978-09-13 |
| SE442953B (sv) | 1986-02-10 |
| AT354632B (de) | 1979-01-25 |
| DE2703620A1 (de) | 1977-08-04 |
| NL179290B (nl) | 1986-03-17 |
| ES455473A1 (es) | 1978-01-01 |
| FR2339621B1 (no) | 1980-06-06 |
| NO770293L (no) | 1977-08-02 |
| JPS6242887B2 (no) | 1987-09-10 |
| NL7700927A (nl) | 1977-08-02 |
| SE7700864L (sv) | 1977-07-31 |
| ATA53277A (de) | 1979-06-15 |
| BE850852A (fr) | 1977-07-28 |
| AR214625A1 (es) | 1979-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4069216A (en) | Simplified methods for preparation of very high purity Factor VIII concentrate | |
| US4188318A (en) | Simplified method for preparation of high yield, high purity Factor VIII concentrate | |
| BE1004178A3 (fr) | Procede de preparation a l'echelle industrielle d'un concentre de facteur von willebrand humain standardise, de tres haute purete, approprie a un usage therapeutique. | |
| US4177188A (en) | Process for recovering purified albumin from blood plasma using PEG and caprylic acid | |
| US20190359650A1 (en) | Methods for extracting keratin proteins | |
| CA1101332A (fr) | Procedes simplifies pour la preparation de concentres de facteur viii de tres grande purete | |
| EP2292656B1 (fr) | Procédé de préparation d'un concentré von Willebrand (fvw) par voie chromatographique et concentré de fvw susceptible d'être ainsi obtenu | |
| CA1054052A (en) | Simplified method for preparation of high yield, high purity factor viii concentrate | |
| FR2489150A1 (fr) | Procede de preparation d'un concentre a forte teneur en facteur viii | |
| EP1037923B9 (fr) | Procede de preparation par filtration d'une solution de facteur viii securisee viralement | |
| CN107709350A (zh) | 纯化和/或病毒灭活的方法 | |
| EP0402205B1 (fr) | Procédé de préparation de solutions d'albumine purifiée | |
| EP0555135B1 (fr) | Procédé de fabrication de fibrinogène de très haute pureté | |
| JP2000053581A (ja) | 減少した凝集物含量を有するタンパク質製剤の製造法および該製剤の使用 | |
| JPS5843371B2 (ja) | ガンマグロブリン ノ セイホウ | |
| FR2473886A1 (fr) | Perfectionnement aux procedes de concentration et de purification du facteur anti-hemophilique (facteur viii) et preparations de facteur viii concentre et purifie obtenues | |
| EP0383645B1 (fr) | Procédé de fabrication du facteur antihémophilique (FVIIIc) ayant une très haute pureté. | |
| EP4073084A1 (en) | Protein bioprocess | |
| FR2479834A1 (fr) | Procede de purification des glucosaminoglucanes | |
| JP6370853B2 (ja) | 免疫グロブリンの調製方法 | |
| FR3090321A1 (fr) | Procédé de filtration du fibrinogène | |
| JPS62195331A (ja) | 血液凝固第８因子製剤の製法 | |
| TW201811815A (zh) | 製備免疫球蛋白溶液的方法及其用途 | |
| DK146098B (da) | Fremgangsmaade til rensning af faktor viii (antihemofil faktor) | |
| WO2004089403A1 (ja) | アルブミン凝集体及び／または不純蛋白質の除去方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |